Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts.

Oncotarget · 2015 · PMC4741939 · PMID 26460958

Europe PMC DOI

hedged sentence

0.0001

closest p · 0.0× alpha

0.0001

boldest claim

The sentences

extremely significantp < 0.0001actually significant

From day 32 the two-tailed p value of L19-IL2/OC-46F2 high dose group compared to OC-46F2 and L19-IL2 groups of mice was extremely significant ( p < 0.0001) and very significant ( p = 0.0037), respectively, indicating the strong efficacy of combined therapy (Figure 7C ).

also in 7,787 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.